The Health Influences of Puberty (HIP) Study

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
ObesityInsulin ResistanceGonadal DysfunctionType 2 Diabetes
Interventions
DRUG

Metformin

After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.

DRUG

Placebo

Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

All Listed Sponsors
collaborator

American Diabetes Association

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

Children's Hospital Colorado

OTHER

lead

University of Colorado, Denver

OTHER

NCT01775813 - The Health Influences of Puberty (HIP) Study | Biotech Hunter | Biotech Hunter